Objectives. To determine whether the spontaneous production of interleukin 6 (IL-6), oncostatin M (OSM ), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) from peripheral blood mononuclear cells (PBMC ) is increased in patients with systemic sclerosis (SSc).
Systemic sclerosis (SSc) is a connective tissue disease tion [5, 6 ] . However, the correlations between production of IL-6 from PBMC and the clinical or laboratory characterized by fibrosis and vascular changes in the features of this disease remain unknown. skin and other visceral organs. Although the pathogenOncostatin M (OSM ) appears to be another novel esis of SSc remains unclear, numerous studies suggest fibrogenic cytokine that is produced by activated human that the progression of this disease is orchestrated by a T cells and monocytes/macrophages [7, 8] . OSM shows cascade of cytokines which play some roles in the multiple biological activities such as growth regulation, processes of inflammation, fibrosis and vascular injury enhancement of IL-6 production and stimulation of [1] . Interleukin (IL)-6 is a cytokine produced by a acute-phase protein production [7] [8] [9] [10] . While some variety of cells, such as T cells, monocytes/macrophages, OSM bioactivities appear to be unique, other biological fibroblasts, endothelial cells and hepatocytes [2] . activities overlap with those of IL-6. OSM has been has been shown to stimulate dermal fibroblasts to proshown to stimulate the synthesis of tissue inhibitor of duce increased amounts of collagen and glycosaminometalloproteinases in fibroblasts of lung or synovial glycan, suggesting that it plays some role in the pathoorigin [11] . It has also been reported that OSM stimugenesis of SSc via stimulation of fibroblasts [3] .
lates collagen and glycosaminoglycan production by Consistently, serum IL-6 is detected more frequently cultured dermal fibroblasts from healthy controls [12] . in patients with SSc than in control subjects [4] .
Gp130, the component of a multiple subunit cell Furthermore, peripheral blood mononuclear cells surface receptor, is a common signal transducer shared (PBMC ) and activated fibroblasts from patients with by IL-6, OSM, leukaemia inhibitory factor (LIF ), IL-11 SSc have been shown to augment levels of IL-6 producand ciliary neutrophilic factor (CNTF ), which are members of a family of pleiotropic cytokines [13] . IL-6
Submitted 29 May 1998; revised version accepted 25 February 1999. cannot bind directly to membrane-bound gp130 and bound gp130, which leads to signal transduction to be elevated when each value was higher than 20 mm/h, 0.5 mg/dl, 1774 mg/dl and 355 mg/dl, respectively. [13] [14] [15] . Therefore, the effect of IL-6 could be enhanced by sIL-6R. On the other hand, sgp130 binds to cytokines listed above, and thereby disturbs the binding of these PBMC cultures cytokines to membrane-bound gp130. Therefore, it has PBMC were isolated from heparinized blood by standbeen suggested that sgp130 inhibits the biological funcard Ficoll-Hypaque gradient centrifugation. PBMC tions of IL-6 and OSM. IL-6R are expressed on a (1×106 cells/ml in RPMI 1640 containing 10% heatnumber of cells, including myeloma cells, T cells and inactivated fetal calf serum and supplemented with macrophages, and sIL-6R is secreted from these cells.
50 U/ml penicillin, 50 mg/ml streptomycin) were cultured Previous studies have demonstrated that serum sIL-6R at 37°C in a 5% CO 2 atmosphere. After 48 h of culture, levels are elevated in some IL-6-related diseases, such as the supernatants were collected by centrifugation and multiple myeloma and HIV infection [16, 17] . In addiwere frozen at −40°C prior to use. tion, we have recently shown that serum sIL-6R are elevated in SSc in comparison with normal controls Enzyme-linked immunosorbent assay [18] . gp130 is expressed by many cell lineages, such as
The production of IL-6, OSM and sIL-6R was measured T cells, B cells and fibroblasts, and sgp130 is also with specific enzyme-linked immunosorbent assay detected in human serum [19] ; however, the clinical ( ELISA) kits (R&D Systems Inc., Minneapolis, MN, significance of sgp130 is poorly understood. In this USA) and soluble gp130 production was also measured study, we investigated whether the production of IL-6, with a specific ELISA kit (Medgenix Diagnostics S.A, OSM, sIL-6R and sgp130 from PBMC was elevated in Belgium), according to the manufacturer's protocol. patients with SSc, and whether they were correlated Each sample was tested in duplicate. Sensitivities of the with the clinical or serological features of this disease.
various assays were as follows: IL-6, 0.7 pg/ml; OSM, 2.1 pg/ml; sIL-6R, 140 pg/ml; sgp130, 18.5 pg/ml.
Statistical analysis

Patients and methods
Mann-Whitney U-tests were used to compare variables between two groups. Percentages were compared by x2 Patients test or Fisher's exact probability test. Spearman's rank Thirty-three patients with SSc (30 women and three correlation coefficient was used to examine the relationmen) and 20 age-matched healthy control subjects (18 ship between two continuous variables. A value of women and two men) were studied. Patients with SSc P < 0.05 was considered significant. were between 10 and 72 yr old (mean age 49). All patients fulfilled the criteria proposed by the American College of Rheumatology (formerly, the American Rheumatism Association) [20] . The patients with SSc Results were grouped according to the classification system Production levels of cytokines from PBMC proposed by LeRoy et al. [21] : 23 patients had limited
The production of IL-6, OSM, sIL-6R and sgp130 in cutaneous SSc ( lSSc) and 10 patients had diffuse cutanepatients with SSc and normal controls is shown in Fig. 1 . ous SSc (dSSc).
Production levels of IL-6 from PBMC were significantly elevated in patients with SSc (median 7400, range Clinical assessment 148-47 000 pg/ml ) when compared to those in normal The clinical and laboratory data reported herein were controls (median 420, range 72-18 800 pg/ml; P < 0.05). obtained at the time the serum samples were drawn.
Similarly, production levels of OSM were significantly Patients underwent a detailed clinical assessment and elevated in patients with SSc (median 138, range the involvement of various organ systems was investi-16.5-1100 pg/ml ) when compared with those in normal gated in each patient. Organ system involvement was controls (median 48.5, range 6.6-205 pg/ml; P < 0.005). defined as described by Steen et al. [22] , with some
In addition, sIL-6R levels were significantly elevated in modifications: lung = bibasilar fibrosis on chest radiopatients with SSc (median 180, range 105-330 pg/ml ) in graphy; oesophagus = hypomotility shown by barium comparison with normal controls (median 125, range radiography; joint = inflammatory polyarthralgias or 48-210 pg/ml; P < 0.05). In contrast, sgp130 levels in arthritis; muscle = proximal muscle weakness and elepatients with SSc (median 875, range 20-4900 pg/ml ) vated serum creatine kinase. Pulmonary function,
were not significantly elevated when compared with including vital capacity ( VC ) and the diffusion capacity normal controls (median 520, range 12-2800 pg/ml ). for carbon monoxide (DLco), were also tested. When
Concerning the subgroups of SSc, production levels the DLco and VC were <75% and <80%, respectively, of IL-6 were significantly elevated in both lSSc (median of the predicted normal values, they were classified as 7400, range 148-47 000 pg/ml ) and dSSc (median 8750, abnormal. Erythrocyte sedimentation rates ( ESR), range 210-41 000 pg/ml ) when compared with controls ( Fig. 1A) . Production levels of OSM were significantly C-reactive protein (CRP), IgG and IgM were considered
F. 1. Production levels of (A) interleukin 6 (IL-6), (B) oncostatin M, (C ) soluble IL-6 receptor (sIL-6R) and (D) soluble gp130 (sgp130) by cultured peripheral blood mononuclear cells from normal controls and patients with limited cutaneous systemic sclerosis ( lSSc) and diffuse cutaneous systemic sclerosis (dSSc). The short bar indicates the median value in each group.
higher in both lSSc (median 96, range 16.5-1050 pg/ml ) 105-310 pg/ml ) when compared with controls ( Fig. 1C ) . In contrast, sgp 130 levels in both lSSc and dSSc (median 220, range 27-1100 pg/ml ) than in normal controls ( Fig. 1B) . Soluble IL-6R levels were (median 800, range 20-4900 pg/ml ) and dSSc patients (median 1250, range 150-2300 pg/ml ) were not signifisignificantly higher in lSSc (median 155, range 105-330 pg/ml ) and dSSc (median 202.5, range cantly elevated when compared with those in controls T 2. Clinical and laboratory features of patients with systemic (Fig. 1D) . Although the levels of each molecule tended sclerosis (SSc) classified according to their production levels of soluble to be higher in dSSc than lSSc, there was no significant ment when compared to those with normal sIL-6R levels Anti-U1 RNP 22% 8% ( Table 2 ). In particular, sIL-6R levels correlated signifi-
cantly with the presence of pulmonary fibrosis. In addi-
tion, patients with elevated sIL-6R levels more
frequently had a decreased %VC than those with normal sIL-6R levels. In patients with SSc, sIL-6R levels were *P < 0.05, **P < 0.0005 vs the patients with normal sIL-6R levels.
negatively correlated with %VC and % DLco (r =−0.54, P < 0.01 and r = −0.56, P < 0.01, respectively; Fig. 2 ). Otherwise, there were no correlations between the levels of any soluble molecules and any clinical or serological features. The production levels of IL-6 correlated significantly with those of OSM (r = 0.44, P < 0.05; Fig. 3 ), but not with sIL-6R or sgp130 in patients with SSc. found between IL-6 production levels and serum IgG levels. This result suggests that augmented IL-6 production may activate B cells and thereby cause increased IgG production frequently observed in patients with SSc. Although serum IL-6 levels correlated with CRP and ESR in a previous study [18] , there was no correlation of IL-6 production by PBMC with CRP and ESR in this study. This suggests that PBMC are not the predominant source of IL-6. Another main finding is that sIL-6R levels were elevated in SSc and were significantly correlated with the severity of pulmonary fibrosis. In our previous report, we demonstrated that elevated serum IL-6 is detected more frequently in patients with pulmonary tion, increased sIL-6R levels in serum and bronchoalveolar lavage fluids have been reported in patients with interstitial lung disease [25] . Since sIL-6R enhances IL-6 Discussion signal transduction, our results suggest that an enhanced production of sIL-6R from PBMC may be associated One of the main findings of this study is the enhanced production of OSM by PBMC from patients with SSc.
with the development of pulmonary fibrosis in SSc. However, augmented signal transduction through IL-6 In addition, elevated OSM levels were significantly correlated with the absence of ACA. Since it is well known is not always associated with pulmonary fibrosis as Denis [26 ] revealed a protective effect of IL-6 against that patients with ACA generally do not show severe clinical features, our findings suggest that enhanced pulmonary fibrosis using a mouse model of hypersensitivity pneumonitis. In contrast to the correlation of OSM from PBMC may be associated with more severe clinical features in SSc. However, we could not detect production levels of sIL-6R by PBMC with pulmonary fibrosis, serum sIL-6R levels did not correlate with the OSM either in sera from most patients or in those from normal controls in our previous study. A possible presence of pulmonary fibrosis [18] . Although the reason for this discrepancy is not clear, it is possible that local explanation of this discrepancy is that serum OSM in patients with SSc may be elevated compared with that production of sIL-6R by PBMC may be associated with pulmonary fibrosis. in normal controls, but still remain under the detection limit of the ELISA. A potential role of increased OSM from PBMC in SSc is stimulation of fibrosis. We have
